Ablynx IPO raises $200M for its nanobody platform effort
Belgian biotech Ablynx has lowered its share price but upsized the number of shares on offer in its US IPO, raising $200 million from its debut. And another $29 million could follow if the underwriters pick up their allotment of 1.7 million shares at the $17.50 price.
Ablynx had pencilled in a $150 million target when it filed the IPO at the beginning of this month. But these can be fast-moving figures these days as a long queue of biotechs turn to an eager investor group for more funds to do development work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.